Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

NCT04418648 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

170

Enrollment

OTHER

Sponsor class

Stopped Since the interim results of the ADRIATIC trial presented at the ASCO Annual Meeting in June 2024, the design of the control group is no longer consistent with current clinical practice.

Conditions

Small Cell Lung Cancer Limited Stage

Interventions

DRUG: Toripalimab

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]